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Abstract
 
Inactivation of the retinoblastoma tumor suppressor protein (pRb) has been implicated in mel-
anoma cells, but the molecular basis for this phenotype has not yet been elucidated, and the sta-
tus of additional family members (p107 and p130, together termed pocket proteins) or the con-
sequences on downstream targets such as E2F transcription factors are not known. Because cell
cycle progression is dependent on the transcriptional activity of E2F family members (E2F1–
E2F6), most of them regulated by suppressive association with pocket proteins, we character-
ized E2F–pocket protein DNA binding activity in normal versus malignant human melano-
cytes. By gel shift analysis, we show that in mitogen-dependent normal melanocytes, external
growth factors tightly controlled the levels of growth-promoting free E2F DNA binding activ-
ity, composed largely of E2F2 and E2F4, and the growth-suppressive E2F4–p130 complexes.
In contrast, in melanoma cells, free E2F DNA binding activity (E2F2 and E2F4, to a lesser ex-
tent E2F1, E2F3, and occasionally E2F5), was constitutively maintained at high levels indepen-
dently of external melanocyte mitogens. E2F1 was the only family member more abundant in
the melanoma cells compared with normal melanocytes, and the approximately fivefold in-
crease in DNA binding activity could be accounted for mostly by a similar increase in the levels
of the dimerization partner DP1. The continuous high expression of cyclin D1, A2, and E, the
persistent cyclin-dependent kinase 4 (CDK4) and CDK2 activities, and the presence of hyper-
phosphorylated forms of pRb, p107, and p130, suggest that melanoma cells acquired the capac-
ity for autonomous growth through inactivation of all three pocket proteins and release of E2F
activity, otherwise tightly regulated in normal melanocytes by external growth factors.
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Introduction
 
In vitro, malignant melanocytes from advanced primary or
metastatic lesions can be defined as cells that have escaped
dependency on external growth factors acutely required by
normal melanocytes, such as fibroblast growth factors
(FGFs)
 
1
 
 (in particular basic FGF, also known as FGF2),
hepatocyte growth factor/scatter factor (HGF/SF), mast/
stem cell growth factor (M/SCF), and endothelins (ET-1–
ET-3; for reviews, see references 1–4). Although the mo-
lecular basis for this aberrant melanoma cell phenotype is
poorly characterized, inactivation of retinoblastoma tumor
suppressor protein (pRb) has been implicated, because pRb
is constitutively hyperphosphorylated or expressed at ex-
tremely low levels in melanoma cells (5, 6). The pRb fam-
ily of proteins (pRb, p107, and p130, termed pocket pro-
teins) are regarded as master regulators of the cell cycle
governing the restriction (R) point, i.e., the point of com-
mitment from quiescence (G0/G1) to DNA synthesis (S)
(7–10). In large part, under normal conditions, growth fac-
tors mediate transit through the G1 phase of the cell cycle
by activating a group of cyclin-dependent kinases (CDKs),
mainly CDK2, CDK4, and CDK6, responsible for phos-
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phorylating and inactivating the pocket proteins (11–14).
The CDK holoenzymes, composed of the kinase subunit in
association with the positive partner cyclins (cyclin A, cy-
clin D, and cyclin E), are negatively regulated by cyclin-
dependent kinase inhibitors (CKIs) from the inhibitor of
CDK
 
 
 
(INK) and Kip/Cip family, and by site-specific phos-
phorylation or dephosphorylation carried out by the CDK
activating kinase (CAK) and Cdc25 phosphatase, respec-
tively (for reviews, see references 15, 16).
Hyperphosphorylation of pocket proteins releases their
suppressive association with five transcription factors from
the E2F family (E2F1–E2F5), leading to the accumulation
of E2F transcriptional activity and upregulation of genes re-
sponsible for cell cycle progression (cyclin A, cyclin D1,
cyclin E, cdc2, p107, and p21
 
CIP
 
), DNA synthesis (dihy-
drofolate reductase and DNA polymerase 
 
a
 
), and transcrip-
tion factors c-MYC, c-MYB, B-MYB, as well as E2F1 and
E2F2, that participate in the induction of early and late re-
sponse genes (10, 17–20). The sixth E2F member, E2F6,
does not associate with pocket proteins, but by itself can act
as a transcriptional repressor of E2F responsive genes, and
can arrest entry into the S phase of the cell cycle when
overexpressed (21–23).
Therefore, we set out to determine E2F activity in nor-
mal versus malignant melanocytes and its regulation by
melanocyte growth factors. Using gel shift analyses, we
demonstrate that E2F2 and E2F4 were the predominant
transcription factors from the E2F family active in prolifer-
ating normal melanocytes, melanoma cells, and freshly iso-
lated melanoma tumors. E2F4, in association with p130
and to a lesser extent pRb, were the predominant growth
inhibitory complexes in growth-arrested normal melano-
cytes. There was upregulation of E2F activity in mela-
noma cells that included, in addition to E2F2 and E2F4,
E2F1 and E2F3 and occasionally E2F5. E2F6 was not de-
tected in either cell type. The release of E2F activity in the
melanoma cells was dependent on persistent CDK activity
that maintained all three pocket proteins in the inactive
forms. Inhibition of this activity by flavopiridol also inhib-
ited melanoma cell proliferation. The unregulated E2F ac-
tivity in melanoma cells is probably sufficient to impart
continuous proliferation even in the absence of external
growth factors required by normal melanocytes. The ab-
sence of E2F6 and the low levels or absence of E2F1 activ-
ity are advantageous to melanoma cells, as these two tran-
scription factors can cause growth arrest or apoptosis when
overexpressed (21–28).
 
Materials and Methods
 
Cell Culture and Proliferation Assay. 
 
Normal human melano-
cytes were dissociated from newborn foreskins and maintained in
Ham’s F-10 medium supplemented with glutamine (2 mM),
penicillin-streptomycin (100 U/ml), and 7% fetal bovine serum
(FBS; all from GIBCO BRL), termed basal medium, that was
further enriched with several ingredients required for optimal
proliferation. They included 12-
 
O
 
-tetradecanoyl phorbol-13-
acetate (TPA, 85 nM), 3-isobutyl-1-methyl xanthine (IBMX, 0.1
 
mM), cholera toxin (2.5 nM), Na
 
3
 
VO
 
4
 
 (1 
 
m
 
M), and 
 
N
 
6,2
 
9
 
-
 
O
 
-dibutyryladenosine 3:5-cyclic monophosphate (dbcAMP, 0.1
mM; Sigma-Aldrich Chemical Co.), termed for short TICVA
(2, 29, 30). Unless otherwise stated, all tests were performed
with first passage melanocytes pooled from 6–12 donors (
 
z
 
4 wk
in culture). To assay the effect of specific peptide growth factors,
normal melanocytes were seeded in 21-cm
 
2
 
 or 55-cm
 
2
 
 Petri
dishes in OptiMEM medium (GIBCO BRL) supplemented
with FBS (2%) without or with bFGF (10 ng/ml), HGF/SF (100
ng/ml), ET-1 (10 nM), or combinations thereof as indicated.
The pigment cells were highly differentiated as judged by the
production of melanin, expression of melanocyte-specific pro-
teins (tyrosinase, gp75/tyrosinase-related protein 1), and den-
dritic morphology.
DNA synthesis was evaluated by the standard [
 
3
 
H]thymidine
assay. Melanocytes were seeded in 24- or 48-well plates, treated
with experimental media for the duration indicated, and then
exposed to MEMS medium containing 5 
 
m
 
Ci/ml [
 
3
 
H]thymidine
(New England Nuclear) for 1 or 4 h (31). Each data point is an
average of triplicate wells; the SD did not exceed 15% of total
counts.
Human metastatic melanoma cells 501 mel, 586 mel,
YUSAC2, YUGEN8, YUSIT1, YUZAZ6, and YUBSM were
maintained in the basal medium consisting of Ham’s F-10 sup-
plemented with glutamine, penicillin-streptomycin, and 7% FBS
(GIBCO BRL) as described (6, 32–34). The cultured melanoma
cells were from early (first or second) or late passage (such as pas-
sage 24 and after). The YU-designated melanoma cells and the
two freshly isolated metastatic melanoma tumors YUBSM and
YUHAWK were provided by Yale University Department of
Surgical Pathology.
To evaluate the growth-inhibitory effect of flavopiridol, a
known CDK inhibitor (35–37), melanoma cells were seeded in
6-well plates, treated with flavopiridol (0, 20, 50, or 200 nM)
and counted with a Coulter counter over a period of 8 d. These
data show averages of duplicate wells.
 
Electrophoretic Mobility Shift Assays.
 
 
 
Normal or malignant me-
lanocytes were seeded in 55-cm
 
2
 
 
 
Petri dishes at 
 
z
 
80% conflu-
ency,
 
 
 
and were exposed to the experimental medium the next
day. For deprivation studies, normal melanocytes were washed
twice with PBS and then seeded in the experimental medium.
Electrophoretic mobility shift assays (EMSAs) were performed
under standard conditions (38, 39) using nuclear extracts, unless
otherwise stated. Extracts (prepared as described [40]) were sub-
jected to two successive 20-min centrifugations at 14,000 rpm in
a microfuge centrifuge at 4
 
8
 
C to remove melanin, as particulate
melanin binds nonspecifically to DNA and interferes with the
binding assay (our unpublished observation). Protein concentra-
tions were determined by the Bio-Rad protein assay, and DNA
binding assays (31, 38) were performed with 4 
 
m
 
g of nuclear
proteins (unless otherwise stated) and end-radiolabeled double-
stranded DNA fragment (1.5–2 
 
3
 
 10
 
5
 
 cpm/assay) containing a
single E2F consensus binding site derived from the dihydrofolate
reductase (DHFR) promoter (sc-2507; Santa Cruz Biotechnol-
ogy), termed E2FRE.
For competition studies, the DNA binding assays also in-
cluded 10 ng of unlabeled E2FRE, mutant E2FRE double-
stranded oligonucleotide with a CG to AT substitution at the
E2F binding motif (E2FREmut, sc-2508), or double-stranded
oligonucleotide containing an MYB response element (MRE) as
a nonspecific competitor (38). To identify the proteins in com-
plex with the E2F consensus site, extracts were preincubated
with rabbit polyclonal antibodies (0.5–2 
 
m
 
g each) to E2F1 (sc- 
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193 X), E2F2 (sc-633 X), E2F3 (sc-878 X or sc-879 X), E2F4
(sc-866 X), E2F5 (sc-1083 X or sc-999 X), E2F6 (sc-8175),
DP1 (sc-610 X), DP2 (sc-829 X), pRb (sc-050 X), p107 (sc-318
X), p130 (sc-317 X), or CDK2 (sc-163), mAb to cyclin A2 (sc-
BF683 X), cyclin E (sc-248 X), or Sp1 (sc-420 X), all from Santa
Cruz Biotechnology. Antibodies to the microphthalmia-associ-
ated transcription factor (MITF) were from David Fisher (Dana-
Farber Cancer Institute, Harvard Medical School, Boston, MA).
Reaction mixtures were loaded onto precast 6% polyacrylamide
DNA retardation gels (NOVEX), and dried gels were exposed
to reflection film (BioMax MR; Eastman Kodak Co.) at room
temperature for 1–2 d.
To estimate fold difference, x-ray films were scanned with a
Computing Densitometer (Molecular Dynamics), and the opti-
cal density of each band was determined after subtracting adja-
cent, cold competition background.
 
Immunoblot Analysis. 
 
For pocket proteins and cyclins, nor-
mal melanocytes and melanoma cells were lyzed in RIPA buffer
containing a cocktail of protease inhibitors (Complete EDTA-
free; Boehringer Mannheim) and phosphatase inhibitors (100
mM NaF, 10 mM Na
 
4
 
P
 
2
 
O
 
7
 
, 1 mM Na
 
3
 
VO
 
4
 
, 0.2 mM ZnCl
 
2
 
and 20 mM 
 
b
 
-glycerol phosphate). Proteins (30–40 
 
m
 
g/lane, as
measured by the Bio-Rad protein assay reagent) were fraction-
ated in 6, 8, or 10% polyacrylamide precast gel (NOVEX) as in-
dicated and Western blotted under standard conditions (34).
Specific antibodies recognizing pRb (IF8), p130, p107, cyclin A
(described above), cyclin E (sc-248; Santa Cruz Biotechnol-
ogy), or actin (A2066; Sigma Immunochemicals) were used at
1 
 
m
 
g/ml.
To assess the levels of E2F and DP1 transcription factors, nu-
clear extracts were prepared as described for gel shift analysis and
subjected to Western blotting (20 
 
m
 
g/lane) using E2F1 mAb
KH95 (Santa Cruz Biotechnology), and the antibodies to E2F2–
E2F6, DP1, and DP2 as described above. Fold differences in
protein expression were estimated by the optical density of the
respective bands as mentioned above.
 
Immune Complex Kinase Assays. 
 
Kinase assays were per-
formed as described (41) with slight modifications. Cells were
collected by scraping, washed in cold PBS supplemented with 50
 
m
 
M Na
 
3
 
VO
 
4
 
, lyzed in buffer (50 mM Hepes, 200 mM NaCl,
pH 7.5, supplemented with the protease and the phosphatase
inhibitors mentioned above, and 2% 3-[(3-chlamidopropyl)-
dimethylammonio]-1-propanesulfonate [CHAPS] or 0.1% Tween
20) and slightly sonicated. After 10 min on ice, the cell lysates
were centrifuged for 10 min at 12,000 rpm, and aliquots of the
supernatants (180–250 
 
m
 
g protein/assay for CDK2 and 500 
 
m
 
g/
assay for CDK4) were incubated with antibodies (2 
 
m
 
g/each)
against CDK2 (M2, sc-163-G; Santa Cruz Biotechnology),
CDK4 (H-22-G, sc-601-G; Santa Cruz Biotechnology), or
p130, using goat or rabbit IgG as a control, for 2 h on ice. Anti-
body–antigen complexes were captured on 50 
 
m
 
l slurry of pro-
tein G–Sepharose beads (GammaBind G; Amersham Pharmacia
Biotech) by rotating for 30 min in the cold. The beads were then
washed successively three times with lysis buffer, and once with
kinase buffer (30 mM Hepes at pH 7.5, 10 mM MgCl
 
2
 
, 1.0 mM
dithiothreitol, 5 mM benzamidine), and the immune complex–
bound beads were incubated with 20 
 
m
 
l kinase buffer supple-
mented with 25 
 
m
 
M ATP and 2 
 
m
 
Ci of [
 
g
 
-
 
32
 
P]ATP (3,000 Ci/
mmol; NEN Research Products), plus 2.5 
 
m
 
g histone (for
CDK2) or 2.5 
 
m
 
g glutathione 
 
S
 
-transferase (GST)-pRb(773–
928) (for CDK4 activity), at 37
 
8
 
C for 30 min. The reactions
were terminated by the addition of 10 
 
m
 
l 3
 
3
 
 SDS sample buffer
and 5 min heating at 95
 
8
 
C. After centrifugation, supernatants
 
were fractionated by SDS-PAGE electrophoresis, and dried gels
were autoradiographed. Histone 1 or GST-pRb(773–928) pro-
tein bands were excised from the gels and radioactivity was mea-
sured in a scintillation counter.
 
Results
 
E2F Binding Activity, Expression Pattern of Pocket Proteins,
and Cyclins in Normal Melanocyte as a Function of External
Stimuli.
 
 
 
We first characterized the pattern of E2F activity
and pocket protein phosphorylation in normal melanocytes
in response to external stimuli, as this has not yet been re-
ported. As shown previously (for a review, see reference 2),
normal melanocytes, unlike melanoma cells from advanced
lesions, rapidly exit the cell cycle when shifted to serum-
supplemented, but growth factor–deprived medium (Fig. 1
A). Under these conditions, exposure to individual growth
factors, such as bFGF or HGF/SF, but not ET-1, promoted
low levels of DNA synthesis that were further enhanced by
costimulation with ET-1 and bFGF, ET-1 and HGF/SF,
bFGF and HGF/SF, or all three factors combined (Fig. 1
A, b; as indicated).
Growth arrest was associated with decreased total E2F
binding activity and a shift in the pattern of E2F complex
formation as revealed by gel retardation assays (Fig. 1 B). A
major, fast migrating E2F binding activity (Fig. 1 B, a, at
bracket) and two additional minor complexes migrating at
intermediate and slower rates (Fig. 1 B, b, solid arrow, and
c, open arrow) were apparent in proliferating melanocytes.
The binding activity in all complexes was due to E2F, as it
was competed out by excess unlabeled E2FRE, but not by
E2FREmut (Fig. 1 B; compare lane 2 to 1 and 3, and lane
10 to 9 and 11).
As starved melanocytes exit the cell cycle, there was a
sharp reduction in complex a after 20 h (Fig. 1 B, lanes 4–8,
at bracket). Complex b persisted for 16 h and was drasti-
cally reduced at 20 h, with little remaining at 24 h of depri-
vation (Fig. 1 B, compare lane 7 to 8 and 6, solid arrow),
time points corresponding to complete inhibition of DNA
synthesis (Fig. 1 A, a). On the other hand, complex c disap-
peared within 5 h of deprivation (Fig. 1 B, compare lane 4
to 1 and 3, open arrow). A new complex that migrated to
an intermediate position between complex b and c became
visible 10 h after deprivation and persisted thereafter (Fig. 1
B, lanes 5–8, 9, and 11, at d, arrowhead). The timing of
complex d coincided with a precipitous drop in DNA syn-
thesis (Fig. 1 A, a).
The levels of complex a also correlated with the extent
of DNA synthesis in medium supplemented with specific
peptide growth factors (compare relevant bands marked
with bracket in Fig. 1 B, lanes 9–18, with the histogram in
Fig. 1 A, b). Interestingly, complex a was more prominent,
and complex c was hardly detected in peptide growth fac-
tor–supplemented medium, compared with TICVA-sup-
plemented medium (compare lane 1 to 12, 13, and 15–18,
open arrow), conditions also associated with higher levels
of DNA synthesis (compare [
 
3
 
H]thymidine incorporation
in Fig. 1 A, a to Fig. 1 A, b). 
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The migration pattern in Western blots analyses revealed
that, as expected, all three pocket proteins became dephos-
phorylated in starved melanocytes, observed as a shift from
slow (hyper-phosphorylated) to fast (hypo- or unphosphor-
 
ylated) migrating forms (Fig. 1 C, as indicated). Loss of
slow migrating forms was clearly visible within 10 h of
deprivation, especially with p130, (Fig. 1 C, compare lane
1 to 3 in panels marked p130 and p107), coinciding with
the appearance of complex d described above (Fig. 1 B,
compare lane 1 to 5, arrowhead). Noticeable changes in
pRb gel migration patterns were detected only 20 h after
deprivation and included the loss of the slow and fast mi-
grating forms and reduction in the total level of the pro-
tein, changes particularly accentuated in peptide growth
factor–supplemented medium (Fig. 1 C, compare lanes 1–4
to 6 and 7, and 11–14 to 7 and 10; panel marked pRb). A
sharp decline in p107 to almost undetectable levels was ob-
served 20 and 24 h after deprivation, time points character-
ized by complete growth arrest, loss of the fast, and accu-
mulation of the slow migrating form of E2F DNA binding
activity, consistent with p107 regulation by E2F1 and E2F2
(42, 43).
The phosphorylation of pocket proteins is coordinated
by the levels of cyclins that bind and activate CDKs, such
as cyclin D1 in complex with CDK4/CDK6, and cyclin A
and E in complex with CDK2 (for reviews, see references
9, 15, 44). However, normal melanocytes are different
from other cell types in that the presence of serum was not
sufficient to maintain high cyclins levels. Cyclin D1 and
cyclin A2 were maintained only in medium supplemented
with serum and TICVA or specific growth factors (Fig. 1
C). Cyclin D1 and A2 levels abruptly disappeared 20 h af-
ter deprivation of TICVA. The gradual decline in cyclin
D1 levels during the initial 16 h of starvation coincided
with the gradual loss of p107 high molecular weight spe-
cies, i.e., highly phosphorylated forms, consistent with loss
of CDK4/6 activity. Synergistic growth factors also syner-
gized in promoting cyclin D1 levels. All together, these re-
sults reflect the accepted paradigm in which E2F activity is
tightly regulated in response to external stimuli required
for melanocyte proliferation, positively correlating with
the intensity of DNA synthesis and the phosphorylation
status of pocket proteins, driven by cyclins and/or CDK
holoenzymes.
 
Identification of the Components in the E2F DNA Binding
Activity. 
 
The addition of specific antibodies to the
EMSA reaction mixtures established that the predominant
species bound to the E2F site in exponentially proliferating
melanocytes were E2F2 and E2F4, as detected by sup-
pressed or supershifted complexes (Fig. 2, compare lanes 1
and 3 to 5 and 7, at bracket; supershift marked by bar).
However, low levels of E2F1, E2F3, and possibly E2F5,
were also present (Fig. 2, compare lanes 1 and 3 to 4, 6,
and 8, at bracket). In medium supplemented with peptide
growth factors (bFGF/HGF/ET-1), E2F4 was still the
most prominent binding activity (Fig. 2, compare lanes 9
and 11 to 15), whereas E2F2, E2F3, and E2F5 were
present to a lesser extent (Fig. 2, lanes 13, 14, and 16), with
E2F1 not detectable (Fig. 2, lane 12). The reduced sup-
pression of DNA binding activity by antibodies to E2F1,
E2F3, or E2F5 was not due to lower binding efficiency, as
these antibodies were effective in EMSA studies with HeLa
Figure 1.  Growth factor regulation of E2F DNA binding activity and
expression of growth-regulatory proteins in normal human melanocytes.
Melanocytes (first passage) were used in parallel to assay for proliferative
responses (A); E2F DNA binding activity (B); and pocket protein and cy-
clin expression (C). (A, a) Melanocytes grown in TICVA/supplemented
basal medium were seeded in 24-well plates (1.4 3 105 melanocytes/well)
in either TICVA-supplemented (0) or deprived medium for the indicated
period of time. [3H]Thymidine incorporation was for 1 h at different time
points as indicated. Data are averages of triplicate wells. SE did not exceed
10%. (A, b) Melanocytes (0.7 3 105) were seeded into 48-well plates and
exposed to OptiMEM medium with or without peptide growth factors.
[3H]Thymidine was added 24 h after the addition of experimental me-
dium for 4 h. Data are averages of triplicate wells normalized to 1 h/1.4 3
105 melanocytes, as in b. Growth factors included: bFGF/FGF2 (H, 10
ng/ml), HGF/SF (F, 100 ng/ml), ET-1 (E, 0.1 mM), or combinations
thereof. NA, no additions. SD did not exceed 13% of total counts. (B)
EMSA of whole cell lysates prepared from melanocytes grown in
TICVA/serum-supplemented medium and harvested at the exponential
phase of growth (lanes 1–3), or after TICVA deprivation for the time in-
dicated (lanes 4–8), as in A, a. Alternatively, melanocytes were incubated
with peptide growth factors as in A, b, and harvested 24 h later (lanes 9
and 10). E2F EMSA reactions contained 4 mg of total cellular proteins
and an end-labeled DNA fragment derived from the DHFR promoter.
Excess (10 ng) unlabeled double-stranded oligonucleotide containing
wild-type E2F responsive element site (E2FRE) or mutant E2FRE
(E2FREmut) were added to gel shift assays where indicated. GF, growth
factor; additional abbreviations as indicated in the legend to A, b. (C)
Western blot analyses of pocket proteins and cyclins of melanocytes
treated as in A, a (lanes 1–6) and A, b (lanes 7–14) with antibodies as indi-
cated. Equal loading of the 6% gel used to fractionate pocket proteins is
indicated by the spurious band (control), whereas equal loading of the
10% used to fractionate the cyclins is represented by actin staining (actin). 
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(data not shown), and as can be seen below with melanoma
cell nuclear extracts.
The antibodies also detected E2F4 in the slow migrating
complex c (Fig. 2, lane 7, open arrow), and E2F1 in com-
plex b (Fig. 2, lane 4, solid arrow). In both culture condi-
tions, the E2Fs were in complex with DP1 (Fig. 2, lane 20;
and Fig. 3 A, lane 17). Because antibodies to pRb, p107,
or p130 had no effect on the fast migrating DNA binding
activity (Fig. 2, lanes 17–19; and Fig. 3 A, lanes 5–8, 14–
16, at bracket), we concluded that complex a contained
unbound E2Fs, termed free E2F or E2F.
Similar analysis showed that pocket proteins were
present in complex b, c, and d. In growth-stimulated me-
lanocytes, the E2F1 containing complex b was inhibited by
anti-pRb but not by anti-p107 or anti-p130 antibodies
(Fig. 3 A, compare lane 1 to 5, solid arrow) and was thus
designated E2F1-pRb. In contrast, complex c was com-
pletely abolished by antibodies to p107 or p130 (Fig. 3 A,
compare lane 1 to 6 and 7, open arrow). In growth-
arrested melanocytes, complex d was reduced by the anti-
pRb antibodies, and was completely abolished by anti-
p107 or anti-p130 antibodies (Fig. 3 A, compare lane 10 to
14–16, arrowhead).
The apparent interference by anti-p107 antibodies with
E2F DNA binding activity in 20 h–deprived melanocytes
(Fig. 3 A, lane 15), coinciding with drastic reduction in
p107 (Fig. 1 C, lane 5), raised the possibility that the anti-
bodies were not specific to p107. Indeed, a reciprocal im-
munoprecipitation and immunoblotting experiment per-
formed with cell extracts prepared from 24–h starved
melanocytes in which p107 was almost undetectable (Fig. 1
C, lane 6) contained ample p130 (data not shown). On the
other hand, antibodies to p130 did not detect p107. There-
fore, we concluded that although complex c may contain
p107 and p130, complex d contained, in addition to pRb,
only p130, very likely both in association with E2F4 (Fig. 3
A, lanes 4 and 13; and Fig. 2, lane 7). This EMSA also con-
firmed that among the DPs, DP1 was the predominant E2F
dimerization partner (Fig. 3 A, lanes 8, 9, 17, 18).
Previous reports showed the presence of multimeric E2F
DNA binding activities in other cell types, such as CDK2–
cyclin A and CDK2–cyclin E in association with p107–E2F
or with p130–E2F (reference 10 [for a review], 18, 19, 45,
46), as well as in the melanoma cell line HO-1 (47). Similar
analysis revealed that indeed CDK2 and cyclin A were in
the E2F4–p130 (or p107) complex c, as visualized by su-
pershifts with the respective antibodies (Fig. 3 B, compare
lane 1 to 3 and 4, supershifts shown by bars). Complex d
was also suppressed by antibodies to CDK2, but there was
no supershift by antibodies to cyclin A (Fig. 3 B, compare
lane 8 to 5 and 7, at arrowhead). Cyclin A was the most
abundant cyclin in the complex, as only low levels of cyclin
E could be detected (Fig. 3 B, compare lane 12 to 13, open
arrow). Multimeric complexes composed of CDK2–cyclin
A with E2F and p107 or p130 are characteristic of cells en-
tering the S phase of the cell cycle (46, 48), consistent with
the proliferative state of the melanocytes. In contrast, E2F4
in complex with pRb or p107 was shown to suppress E2F-
dependent transcription and to mediate growth arrest (49),
Figure 2.  Identification of the components in the E2F DNA binding
activity in nuclear extracts. Gel shift analyses of melanocytes grown in
TICVA-supplemented basal medium (lanes 1–8), or in OptiMEM sup-
plemented with 2% FBS and peptide growth factors bFGF/FGF2, HGF/
SF, and ET-1, for 24 h. E2F EMSA reactions contained 4 mg of nuclear
proteins and an end-labeled DNA fragment as described in the legend to
Fig. 1. Antibodies specific for each of the E2F family members, E2F1–
E2F5, or each of the pocket proteins, pRb, p107, or p130, or the E2F
dimerization partner, DP1, were added to the binding reactions as indi-
cated to identify proteins in specific complexes. Bracket marks free E2F
species, solid and open arrows (marked b and c, respectively) point at
complex E2F binding activity, and bars on the left and right of the figure
mark the positions of the supershifts. Figure 3.  Gel shift analyses of nuclear extracts from stimulated versus
growth-arrested melanocytes. (A and B) Melanocytes grown in TICVA
plus serum-supplemented medium were harvested at the exponential
phase of growth (Stimulated), or after transfer to basal medium without
TICVA, for 20 h (Deprived [20 h]). E2F EMSA reactions contained end-
labeled DNA fragment derived from the DHFR promoter, 4 mg of nu-
clear proteins, cold competitors, or antibodies, where indicated and as de-
scribed above. Free E2F binding activity is marked by brackets (free E2F),
and complex activities by solid (E2F1-pRb) and open arrows (c, or E2F4
Multi-complex), and arrowhead (d). Antibodies to specific proteins were
added to the reaction mixtures as indicated. Bars mark the supershifts. 
1010
 
Deregulation of E2F in Melanomas
 
and E2F in association with p130 was also detected in HO-1
melanoma cells undergoing growth arrest and differentia-
tion in response to interferon (IFN-
 
b
 
) plus mezerein treat-
ment (47). All together, these results demonstrate that
growth factors tightly control E2F DNA activity in normal
melanocytes, with E2F2 and E2F4 being the major species.
Growth arrest was associated with low levels of free E2F
and the accumulation of pRb and p130 suppressive com-
plexes, possibly in association with E2F4.
 
Aging-dependent Changes in E2F Binding Activity in Normal
Melanocytes. 
 
Normal human melanocytes, unlike mela-
noma cells, have a definite life span in culture and become
progressively unresponsive to external growth stimuli (50,
51, and our unpublished results). Since all of the experi-
ments described above have employed highly proliferating
first
 
 
 
passage melanocytes, we extended the gel shifts analyses
to fourth passage melanocytes. Indeed, late passage melano-
cytes grown continuously in the presence of TICVA (
 
z
 
12
population doubling times representing 
 
z
 
3 mo in culture)
displayed a pattern of E2F DNA binding activity similar to
that of growth-arrested first passage melanocytes (Fig. 4,
compare first to late passage cells at bracket). Here again,
free E2F was composed mostly of E2F4, and to lesser extent
E2F2, both present at lower levels than in first passage me-
lanocytes (Fig. 4). pRb-associated complexes were not de-
tected (Fig. 4, lane 17), but E2F4, in association with p130,
was present (Fig. 4, lanes 11, 18, 19, and 29). The anti-p107
suppressive effect is likely due to cross-reactive activity with
p130, as p107 was hardly detected in fourth passage me-
lanocytes (see Fig. 6 C). There was no change in DP1 activ-
ity (Fig. 4, lane 16). These results suggest a diminishing
ability to respond to external growth factors as the cells age
in culture.
 
Free E2F Binding Activity Is Abundant in Melanoma Cells
and Tumors.
 
 
 
The persistent phosphorylation of pRb com-
monly observed in melanoma cells (5, 6) is expected to re-
lieve E2F–pRb transcriptional repression and to generate
free E2F activity. Indeed, the gel retardation assays revealed
uniformly abundant unbound E2F in nuclear extracts from
two uncultured melanoma tumors and seven cultured mela-
noma cell strains, represented by selected examples in Fig. 5
(at brackets). As judged by the level of displacement of the
E2F complex with specific antibodies, E2F2 and E2F4 were
again, invariably, the predominant DNA binding proteins
(Fig. 5 A, lanes 9, 11, 17, and 19; B, lanes 6 and 8; and C,
lanes 6 and 8). However, the other E2F family members
were also present; E2F1, E2F3, and E2F5 were detected in
Figure 4.  A shift to growth-arrest pattern of E2F DNA
binding activity in senescing normal melanocytes. Nuclear
extracts were prepared from fourth (lanes 2–19, 25–29) or
first passage melanocyte cultures grown in TICVA-supple-
mented basal medium and harvested at the exponential
growth phase. DNA binding reactions contained 0–8 mg
of nuclear proteins (as indicated) and an end-labeled DNA
fragment derived from the DHFR promoter as described
above. The reaction mixtures contained excess (10 ng)
double-stranded oligonucleotide encoding wild-type E2F
site (E2FRE), the unrelated MRE site, or specific antibod-
ies as indicated. Brackets and arrowheads point at the posi-
tions of the free E2F and E2F4-p130 suppressive com-
plexes, respectively. The position of E2F1–pRb and the
multimeric E2F4–p130 (p107)/cyclin A–CDK2 are indi-
cated by solid and open arrows, respectively.
Figure 5.  Free E2F DNA binding activity is abundant in melanoma
cells and tumors. Nuclear extracts (A, 0–8 mg/assay; B and C, 4 mg/assay)
from metastatic melanoma cells (501 mel, YUGEN8, and YUSAC2) or a
freshly isolated melanoma tumor (YUHAWK) were used in EMSAs as
described above. All cells in culture were from the exponential growth
phase. Excess unlabeled competitors or specific antibody were added to
the reaction mixtures as described above. Complexes are marked as
above. NA, reaction contained radioactive E2FRE without cell extracts
or any other additions. 
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melanoma 501 mel (Fig. 5 A, lanes 8, 10, and 12), E2F1
and E2F3 in YUGEN8 (Fig. 5 A, lanes 16 and 18), E2F3 in
YUSAC2 (Fig. 5 B, lane 7), and E2F5 was detected at high
levels in the melanoma tumor YUHAWK (Fig. 5 C, lane
9). These binding activities represented free E2F because
antibodies to pocket proteins or to CDK2/cyclins had no
effect (Fig. 5 A–C, antibodies as marked). There were no
differences in the pattern of E2F binding activity between
cultured cells and freshly isolated tumor derived from the
same patient (data not shown).
Nuclear extracts from melanoma cells also contained low
levels of the b and c E2F complexes described in proliferat-
ing normal melanocytes. Displacement of the complexes by
antibodies showed that, as before, complex b represented
E2F bound to pRb (as in Fig. 5 B, lane 13), and complex c
contained E2F in association with p130 (and possibly p107),
CDK2, and cyclin A (Fig. 5 B, lanes 14, 15, 19, and 20).
The E2F4-p130/pRb complex d, characteristic of growth-
arrested melanocytes, was not detected. The effects of the
antibodies were specific, as no suppression or supershift was
observed by antibodies to the transcription factors Sp1 and
MITF (Fig. 5 B, lanes 24 and 25), reported to associate with
pRb (52, 53).
 
Persistent Hyperactivity of E2F DNA Binding in Melanoma
Cells: The Consequence of Continuous Pocket Protein Hyper-
phosphorylation and DP1 Overexpression.
 
 
 
Parallel EMSAs
showed that the persistent E2F DNA binding activity in
melanoma cells, free as well as in multimeric complexes,
was 
 
z
 
5–10-fold higher compared with the first passage
proliferating normal melanocytes (Fig. 6 A, compare lane 1
and 3 to 4 and 6) and with fourth passage melanocytes (Fig.
6 A, compare lane 7 and 9 to 10 and 12), as estimated by a
scanning densitometer.
To determine the cause of this persistently high activity,
we assessed the levels of E2Fs, DPs, pocket proteins, cy-
clins, and CDK activity. Western blots of the six E2Fs and
two DPs family members revealed that E2F1, E2F2, and
E2F3 were present only in growth factor–stimulated normal
melanocytes, but were constitutively expressed in melano-
mas cells exposed to the same medium as “deprived” me-
lanocytes (Fig. 6 B, compare lane 1 to 2–6 of the respective
blots). In normal human melanocytes, E2F4 was expressed
regardless of culture conditions at even slightly higher levels
compared with melanoma cells (Fig. 6 B, compare lane 1
and 2 to 3–6, blot marked E2F4). E2F5 was slightly in-
duced by growth factors in normal human melanocytes, but
it was not overproduced in melanoma cells, and E2F6 was
not detected in either cell type (data not shown). Most im-
portantly, the immunoblots clearly showed an approxi-
mately fourfold increase in the abundance of the dimeriza-
tion partner DP1 in melanoma cells over proliferating
normal melanocytes (Fig. 5 B, compare lane 2 to 3–6). The
higher levels of this dimerization partner, absolutely re-
quired for E2F DNA binding activity, are probably the ma-
jor reason for the approximately fivefold increase in E2F2/4
DNA binding activity in the melanoma cells, as the levels of
the respective proteins are similar in proliferative normal
and malignant melanocytes (Fig. 5 B, compare lane 2 to 3–6).
As with the gel shift, DP2 was not detected by this method
as well (data not shown).
The phosphorylation state of the three pocket proteins
assessed by their pattern of migration in Western blots con-
firmed previous observations (5, 6), that all forms (unhypo-
and hyperphosphorylated) of pRb were more abundant in
melanoma cells compared with normal melanocytes (Fig. 6
C). Likewise, the three melanoma cell lines also expressed
higher levels of all forms of p107 and p130, as well as cyclin
A and cyclin E (Fig. 6 C). Interestingly, growth-stimulated
fourth passage melanocytes displayed pocket protein and
cyclin expression patterns similar to that of growth-arrested
first passage melanocytes (Fig. 6 C, compare lane 4 to 1 and
Figure 6.  Upregulation of E2F DNA binding activity in proliferating
melanoma cells compared with normal melanocytes as a function of
pocket protein and E2F expression. (A) EMSA showing the relative
amounts of E2F DNA binding activity in normal melanocytes (NM, first
and fourth passage) compared with melanoma cells YUSAC2 (SAC2), all
harvested at the exponential growth phase. Each reaction mixture con-
tained 4 mg nuclear proteins, radiolabeled probe, and/or competitors
(where indicated) as described above. Normal melanocytes were grown
in TICVA-supplemented basal medium, whereas melanoma cells
YUSAC2 were grown in basal medium without TICVA. (B) Expression
of E2F1–E2F5 and DP1 in normal melanocytes compared with mela-
noma cells. Shown are Western blots with the respective antibodies (as
marked) using nuclear extracts (prepared as described for gel shift analysis)
harvested from exponentially growing (1) or 24 h TICVA–deprived nor-
mal melanocytes (NM), or from proliferating melanoma cells YUSIT1
(SIT1), YUGEN8 (GEN8), 501 mel (501), or 586 mel (586). Proteins
were fractionated in 8% polyacrylamide precast gels. Equal protein load-
ing is indicated by staining of a spurious band (Control). (C) Western
blots of pocket proteins and cyclins using whole cell extracts from normal
melanocytes (NM, first or fourth passage), harvested at the exponential
growth phase (0), or 10 or 24 h after exposure to TICVA-deprived basal
medium (Dep 10, 24), also used to grow the melanoma cells 501 mel
(501), YUSAC2 (SAC2), and YUGEN8 (GEN8). Proteins were fraction-
ated in 8% polyacrylamide precast gels. Actin staining was used to indicate
the loading in each well. 
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3), in agreement with the pattern and low levels of free E2F
activity (Fig. 6 A, lanes 7–9, and Fig. 4).
Since cyclin D1 was shown previously to be persistently
present in melanoma cells (6), we presumed that the release
of E2F activity in these cells was due to persistent activity
of cyclin D1–CDK4/CDK6, cyclin A–CDK2, and cyclin
E–CDK2, known to coordinate the continuous phosphor-
ylation and/or inactivation of the three pocket proteins
(for reviews, see references 9, 15, 44). This assumption was
confirmed, as shown by the immune complex kinase assays
(Fig. 7). The activity of CDK4, CDK2, and p130-associ-
ated kinase was not dependent on growth factors in the
three melanoma cell lines tested, but was drastically re-
duced (CDK2 and p130-associated kinase) or undetected
(CDK4) in normal melanocytes deprived of growth factors
for 24 h. Furthermore, CDK4 activity was 10–15-fold
higher in the melanoma cell lines compared with prolifer-
ating melanocytes.
 
Inhibition of CDK Activity by Flavopiridol Arrests Melanoma
Cell Growth Mediated by Downregulated E2F Activity. 
 
We
reasoned that if melanoma cell proliferation is driven by the
persistent activity of CDKs, the cells should be efficiently
arrested by agents that inhibit CDK activity, such as fla-
vopiridol (35–37). Indeed, exposure of melanoma cells
YUSIT1 and YUGEN8 (as well as others not shown) to
200 nM flavopiridol, levels known to completely inhibit
CDK activity (36), induced growth arrest (Fig. 8 A). West-
ern blot analysis revealed progressive loss of phosphorylated
forms of pRb, p107, and p130, as well as reduction in pRb
and p107 protein levels in response to flavopiridol (Fig. 8
B), reminiscent of growth factor–deprived normal melano-
cytes (Fig. 1 C) and confirming results obtained by others
for pRb and p107 (35). However, for the first time we
show here the strong impact of flavopiridol on E2F activ-
ity. The gel shift analysis demonstrated a sharp decrease in
free E2F binding activity that affected the four E2Fs’ bind-
ing activity in the melanoma cells, i.e., E2F1, E2F2, E2F3,
and E2F4 (Fig. 8 C, compare lanes 1–8 to 9–16, at
bracket). Furthermore, the complex containing E2F1 in as-
sociation with pRb (formerly designated complex b) accu-
mulated in response to flavopiridol (Fig. 8 C).
 
Discussion
 
Here, for the first time, we characterized the regulation
of E2F DNA binding activity in normal human melano-
cytes in response to growth factors compared with melanoma
Figure 7.  CDK activity in normal melanocytes versus melanoma
cells. Immune complex kinase assays were performed with cell extracts
from first passage normal melanocytes (NM) harvested 24 h after TICVA
starvation (GF2, lanes marked 1) or at the exponential growth phase
(GF1, lanes marked 2), and from melanoma cells YUGEN8 (GEN8,
lanes marked 3), 586 mel (586, lanes marked 4), or YUZAZ6 (ZAZ6,
lanes marked 5), grown in TICVA-deprived basal medium (GF2). Anti-
bodies to CDK4, CDK2, p130, control goat (for CDK4 and CDK2), or
rabbit IgG (for p130), are as indicated. Autoradiograms show radioactive
substrates representing GST-pRb(773–928) in the case of CDK4, or his-
tone 1 in the case of CDK2 and p130 immune complex kinase assays.
The histograms represent the radioactivity in the excised substrate bands
of anti-CDK4, CDK2, or p130 immune complex minus the respective
control antibody.
Figure 8.  Flavopiridol suppresses melanoma cell growth, pocket pro-
tein phosphorylation, and E2F DNA binding activity. (A) Growth–response
to flavopiridol. Metastatic melanoma cells YUSIT1 and YUGEN8 were
seeded in basal medium without (j) or with (d) 200 nM flavopiridol in
6-well plates. Cell were harvested at the indicated times and counted with
the Coulter counter. Each data point is an average of two wells. (B) Pro-
gressive dephosphorylation of pocket proteins in response to flavopiridol.
Melanoma cells YUGEN8 were exposed to 200 nM flavopiridol and har-
vested at the indicated time. Proteins were fractionated in 6% polyacryla-
mide precast gels and Western blotted with the indicated antibodies. A
spurious band is presented to indicate protein loading in each well. (C)
Reduction in total E2F activity in response to flavopiridol. Melanoma
cells YUGEN8 were exposed to 200 nM flavopiridol and harvested 16 h
later. Whole cell lysates (4 mg/assay) were subjected to EMSA in the ab-
sence or presence of competitors or antibodies as described above. The
positions of complexes containing free E2F (E2F) or E2F1–pRb are indi-
cated, and supershifts are marked with bars.1013 Halaban et al.
cells and tumors. We show that in highly proliferating nor-
mal melanocytes, binding activity to an oligonucleotide
probe comprising a single E2F consensus site is due mostly
to E2F2 and E2F4, and to a lesser extent, to E2F1 and
E2F3. In growth-arrested melanocytes, total levels of E2F
DNA binding activity declined, and E2F4 in complex with
p130, and to a lesser extent with pRb, accumulated. Unex-
pectedly, the presumably transcriptionally suppressive E2F1–
pRb complexes were more abundant in proliferating com-
pared with growth-arrested melanocytes. Furthermore, we
show that tumor-dependent changes in melanoma cells in-
cluded upregulation of E2F2 and E2F4 DNA binding ac-
tivity, and to various extents, also that of E2F1, E2F3, and
E2F5. Except for E2F1, the increase in E2F DNA binding
was not due to increased expression of the respective E2F
members, but rather to a proportional increase in the ex-
pression of the dimerization partner DP1.
All three pRb family members were highly abundant in
their hypo- and hyperphosphorylated forms in the mela-
noma cells tested. In melanoma cells, the tumor-suppressor
pocket proteins were inactivated by continuous CDK ac-
tivity driven by the persistent presence of high levels of at
least three cyclins, cyclin D1, cyclin A2, and cyclin E. Inhi-
bition of CDK activity in melanoma cells by flavopiridol-
induced growth arrest was accompanied by reduction in
free E2F activity and an increase in E2F1–pRb transcrip-
tional suppressive complexes. Therefore, we suggest that
melanoma cell autonomy is supported by dysregulated
cyclins that lead to upregulation of E2F transcriptional ac-
tivity.
Low levels of E2F1–pRb complexes, potentially with
transcriptional suppressive function, were observed in pro-
liferating normal and malignant melanocytes. Although in
contradiction to present models of cell cycle control, such
complexes were observed already in proliferating mouse
embryo fibroblasts (54), hyperproliferative primary kerati-
nocytes derived from transgenic K5 E2F1 mice expressing
up to 80-fold more E2F1 than nontransgenic keratinocytes
(55), and in the cytokine-dependent 6-1 pro-B lymphoid
cell line (56). Interestingly, the lymphoid cell line also
shares other characteristics with the melanocyte–melanoma
system, in that growth inhibition was mediated by p130-
containing complexes, and acquisition of cytokine inde-
pendence by E2F4-driven transcriptional stimulation (56).
Constitutive CDK4 and CDK2 kinase activities are the
likely cause for the highly phosphorylated forms of pocket
proteins in melanoma cells, as shown here by the immune
kinase assays of the respective complexes. It is possible that
a combination of genetic alterations frequently encoun-
tered in melanomas, i.e., loss of the CKI p16INK4A (for re-
views, see references 6, 57, 58) and aberrant expression of
the protooncogene bFGF/FGF2 (for a review, see refer-
ence 2) are the cause for persistent CDK activity. Ectopic
expression of bFGF activates the FGFR1, which in turn
can induce high levels of the positive CDK regulators cy-
clin D1, cyclin A, and cyclin E, frequently observed in
melanoma cells (6, and results shown here). Constitutive
expression of cyclins can be the major culprit for melanoma
cell–dysregulated proliferation, since loss of p16INK4A by it-
self is not sufficient to alter the cell dependency on growth
factors (31) or to induce melanomas in humans (58). In
contrast, cyclin D1 is capable by itself of inducing constitu-
tive CDK activity (59, 60), and overexpression of cyclin E
induced S phase and cell division, independently of E2F ac-
tivation (61). In breast cancer cells, overexpressed cyclin E,
in complex with CDK2, can replace the loss of cyclin
D–dependent kinase complexes in maintaining persistent
pRb phosphorylation (62). In melanomas, continuous ex-
pression of cyclin D1 is not solely due to genetic alteration,
as amplification of chromosomal region 11q13, the site of
cyclin D1 (previously PRAD1), occurs in only 1 out of 10
melanomas (63, 64). Thus, high levels of cyclin D1, cyclin
A, and cyclin E in melanoma cells must be the result of in-
creased synthesis and/or decreased degradation.
The persistently high free E2F activity and lack of E2F-
p130 inhibitory complexes in melanoma cells, even in the
absence of external growth factors, most likely contribute
to their ability to proliferate by affecting the expression of
several target genes known to be required for cell cycle
progression. One of these genes, B-MYB, known to be
mostly affected by deletion of p107/p130, may have a par-
ticular significance. B-MYB expression was 25-fold higher
in quiescent p107/p130 double null mouse embryo fibro-
blasts compared with controls (54). We found that c-MYB
and B-MYB mRNA are overexpressed in melanoma cell
lines compared with normal melanocytes, and that ectopic
expression of murine c-MYB in SK-MEL-2 human mela-
noma cells resulted in increased expression of FGF2
mRNA and FGF2 protein (38). Therefore, it is possible
that E2F transcriptional activity and elimination of E2F4–
p107/p130 transcriptional repression set in motion a loop
of autoregulatory gene expression that further enhances the
malignant phenotype.
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